These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 27420111)

  • 21. Something Old, New, Borrowed, Blue: Anthracenedione Agents for Treatment of Multiple Sclerosis.
    Koffman BM; Hacker M; Gunning WT; Quinn A
    Clin Neuropharmacol; 2016; 39(2):102-11. PubMed ID: 26966886
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-Term Response and Remission with Pixantrone in Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma: Post-Hoc Analysis of the Multicenter, Open-Label, Randomized PIX301 Trial.
    Pettengell R; Coiffier B; Egorov A; Singer J; Sivcheva L
    Clin Drug Investig; 2018 Jun; 38(6):527-533. PubMed ID: 29564722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas.
    Sancho JM; Navarro B; Soler Campos JA; de Oteyza JP; de Barrenetxea Lekue C; Bregni M; Grasso Cicala S; Spione M; Mombiedro C; Soler B; Zinzani PL
    Eur J Haematol; 2020 May; 104(5):499-508. PubMed ID: 31997425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort.
    Srokowski TP; Liebmann JE; Modiano MR; Cohen GI; Pro B; Romaguera JE; Kuepfer C; Singer JW; Fayad LE
    Cancer; 2011 Nov; 117(22):5067-73. PubMed ID: 21681734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer (NCCTG N1031, Alliance).
    Sideras K; Hillman DW; Giridhar K; Ginos BF; Tenglin RC; Liu H; Chen B; Tan W; Gross GG; Mowat RB; Dueck AC; Perez EA; Moreno-Aspitia A
    Oncologist; 2022 Apr; 27(5):338-e368. PubMed ID: 35445723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Formaldehyde-activated Pixantrone is a monofunctional DNA alkylator that binds selectively to CpG and CpA doublets.
    Evison BJ; Chiu F; Pezzoni G; Phillips DR; Cutts SM
    Mol Pharmacol; 2008 Jul; 74(1):184-94. PubMed ID: 18413664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nuclear Trapping through Inhibition of Exosomal Export by Indomethacin Increases Cytostatic Efficacy of Doxorubicin and Pixantrone.
    Koch R; Aung T; Vogel D; Chapuy B; Wenzel D; Becker S; Sinzig U; Venkataramani V; von Mach T; Jacob R; Truemper L; Wulf GG
    Clin Cancer Res; 2016 Jan; 22(2):395-404. PubMed ID: 26369630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pixantrone: a promising drug in the treatment of non-Hodgkin lymphomas.
    El-Helw LM; Hancock BW
    Future Oncol; 2009 May; 5(4):445-53. PubMed ID: 19450173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pixantrone, a new anticancer drug with the same old cardiac problems? An in vitro study with differentiated and non-differentiated H9c2 cells.
    Reis-Mendes A; Alves M; Carvalho F; Remião F; Bastos ML; Costa VM
    Interdiscip Toxicol; 2018 May; 11(1):13-21. PubMed ID: 30181708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper.
    Zinzani PL; Corradini P; Martelli M; Minotti G; Oliva S; Spina M; Barosi G; Tura S
    Eur J Haematol; 2016 Dec; 97(6):554-561. PubMed ID: 27124765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas.
    Volpetti S; Zaja F; Fanin R
    Onco Targets Ther; 2014; 7():865-72. PubMed ID: 24926199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pixantrone induces cell death through mitotic perturbations and subsequent aberrant cell divisions.
    Beeharry N; Di Rora AG; Smith MR; Yen TJ
    Cancer Biol Ther; 2015; 16(9):1397-406. PubMed ID: 26177126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tolerability and toxicological profile of pixantrone (Pixuvri®) in juvenile mice. Comparative study with doxorubicin.
    Longo M; Della Torre P; Allievi C; Morisetti A; Al-Fayoumi S; Singer JW
    Reprod Toxicol; 2014 Jul; 46():20-30. PubMed ID: 24602559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bbr 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity.
    Beggiolin G; Crippa L; Menta E; Manzotti C; Cavalletti E; Pezzoni G; Torriani D; Randisi E; Cavagnoli R; Sala F; Giuliani FC; Spinelli S
    Tumori; 2001; 87(6):407-16. PubMed ID: 11989596
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patients' decision-making, experiences and preferences regarding pixantrone treatment in relapsed or refractory diffuse large B-cell lymphoma: study protocol for a longitudinal mixed methods study.
    van Hoogdalem LE; Siemes C; Lugtenburg PJ; Busschbach JJV; Ismail SY
    BMJ Open; 2019 May; 9(5):e026505. PubMed ID: 31122976
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pixantrone demonstrates significant in vitro activity against multiple myeloma and plasma cell leukemia.
    Willenbacher E; Jöhrer K; Willenbacher W; Flögel B; Greil R; Kircher B
    Ann Hematol; 2019 Nov; 98(11):2569-2578. PubMed ID: 31628518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of anthracenediones and their photoaffinity analogs.
    Chou KM; Krapcho AP; Horn D; Hacker M
    Biochem Pharmacol; 2002 Mar; 63(6):1143-7. PubMed ID: 11931847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro modeling of the structure-activity determinants of anthracycline cardiotoxicity.
    Menna P; Minotti G; Salvatorelli E
    Cell Biol Toxicol; 2007 Jan; 23(1):49-62. PubMed ID: 17031515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Limited efficacy of pixantrone in refractory diffuse large B-cell lymphoma.
    Novakovic A; Boltezar L; Novakovic BJ
    Oncol Lett; 2020 Mar; 19(3):2028-2034. PubMed ID: 32194699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of anthracyclines in the era of targeted therapy.
    Cortés-Funes H; Coronado C
    Cardiovasc Toxicol; 2007; 7(2):56-60. PubMed ID: 17652804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.